Interview with Paul Flapper, General Manager, Shire International Licensing BV…
Shire has many offices in America, Europe, as well as in Singapore, in Japan and in Australia. The group has a vast global network and a strong presence in these…
Address: Strawinskylaan six hundred fifty-nine
1 077 XX Amsterdam
,Netherlands
Tel: +31 (0) 20 364 00 74
Web: http://www.shirenederland.nl/
Shire is a global specialty biopharmaceutical company founded in 1986. Shire aims those with life-limiting illnesses helping a better life.
Shire seeks to achieve this through multiple therapeutic areas in medicine specialist to develop, produce and sell. Shire’s activities are housed in two divisions:
‘Human Genetic Therapies’ focused on genetic diseases such as Hunter syndrome, Fabry disease and hereditary angioedema.
Specialty Products’ represents the therapeutic areas of ADHD, Nephrology, Hematology and Gastroenterology.
Shire group is structured as two autonomous businesses supported by global corporate functions; business unit structure that enables small molecule entities to thrive under Shire Specialty Pharma and protein therapeutics to emerge from Shire Human Genetic Therapies
Shire Human Genetics Therapies delivers medicine in the therapeutic area lysosomal storage diseases, namely Fabry disease and Hunter syndrome.
Shire has many offices in America, Europe, as well as in Singapore, in Japan and in Australia. The group has a vast global network and a strong presence in these…
Kees Smaling, Managing Director of Siemens Healthcare, which recently completed its first Dutch (and European) hospital financing, explains the strategic thinking that sustains Siemens’ shift to become a more comprehensive…
DB Schenker’s Bart Coenen (BC) and Vincent Coolen (VC) explain the company’s Vision 2020 and talk about the benefits for pharma companies of outsourcing their supply chain. In 2013, DB…
Floris Van Haselen, Business Development Director Europe for O&M Movianto, one of the rare logistics companies to be fully specialized and to only operate in the healthcare sector, explains how the company…
Peter Schoevers, CEO and co-founder of Julius Clinical, explains how this innovative and thriving organization allies the academic strength of an ARO with the business-oriented leadership of a CRO. Julius…
Isabelle de Walsche, Managing Director of Gedeon Richter Benelux, provides us with an update on the development of this striving and ambitious player in the women’s healthcare field and shares…
Roeland Van Dam, CEO of Bilthoven Biologicals, a historical Dutch company which remains at the forefront of vaccine production, explains how being integrated into the Serum Institute of India has…
Rob de Roock, Director CL Healthcare for UPS Europe, gives us a brief outline of the current market dynamics impacting the booming European healthcare logistics industry and explains how UPS…
Han Brouwer, General Manager for Actelion in the Netherlands, explains how Opsumit’s successful market launch has strengthened Actelion’s leadership position in the pulmonary arterial hypertension (PAH) field. He calls for…
Bart van de Kerkhof highlights how Covidien’s acquisition will drive Medtronic to new heights thanks to a broader product portfolio. Medtronic is already piloting projects and cooperating with key stakeholders to…
Anita Atema, General Manager of Celgene, reveals Celgene’s inspiring and concrete initiatives that illustrate how a true willingness to cooperate with healthcare stakeholders and a remarkable effort of transparency can help…
Amgen Netherlands is preparing to launch five new products next year, including their leading cardiovascular biotech product Repatha and recently announced the acquisition of the Dutch biotech Dezima. General manager…
Maikel Beerens, CEO and founder of Xilloc, a promising Dutch company that designs patient-specific implants, anatomical models and surgical guides for bone reconstruction or augmentation with the help of 3-D…
See our Cookie Privacy Policy Here
